Products - Diabetes | Topic

Showing 14 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: In developmentRemove ‘Status: In development’ filter

Diabetic retinopathy - ruboxistaurin [ID382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macular oedema (diabetic) - pegaptanib sodium [ID452]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Diabetes - buccal insulin [ID311]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab for treating diabetic retinopathy [ID1592]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Diabetes update
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Diabetes in pregnancy: management from preconception to the postnatal period
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Type 1 diabetes in adults: diagnosis and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Type 2 diabetes in adults: management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sotagliflozin for treating type 2 diabetes [ID1657]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Diabetes Products

Filter

Product type
1 selected

Guidance programme

Status
1 selected

New and updated

Showing 14 products

Diabetic retinopathy - ruboxistaurin [ID382]

Macular oedema (diabetic) - pegaptanib sodium [ID452]

Diabetes - buccal insulin [ID311]

Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

Ranibizumab for treating diabetic retinopathy [ID1592]

Diabetes update

Diabetes in pregnancy: management from preconception to the postnatal period

Type 1 diabetes in adults: diagnosis and management (update)

Type 2 diabetes in adults: management (update)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

Sotagliflozin for treating type 2 diabetes [ID1657]

Diabetes Products

Filter

Product type1 selected

Guidance programme

Status1 selected

New and updated

Showing 14 products

Product type
1 selected

Status
1 selected